Article
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Cancer research - 1 Feb 2012
Yang Hong, Higgins Brian, Kolinsky Kenneth, Packman Kathryn, Bradley William D, Lee Richard J, Schostack Kathleen, Simcox Mary Ellen, Kopetz Scott, Heimbrook David, Lestini Brian, Bollag Gideon, Su Fei
Abstract excerpt
The protein kinase BRAF is a key component of the RAS-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation, and survival. Mutations in BRAF at codon 600 promote catalytic activity and are associated with 8% of all human (solid) tumors, including 8% to 10% of colorectal cancers (CRC). Here, we report the preclinical characterization of vemurafenib (RG7204; PLX4032;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.